Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders

European Neurology

Volumn 55, Issue 4, 2006, Pages 204-208

  Hurnaus, S ^a   Mueller Felber, W ^a   Pongratz, D ^a   Schoser, B G H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Intravenous immunoglobulins; Intravenously applied immunoglobulin therapy; Matrix metalloproteinases; Neuromuscular disorders; Tissue inhibitor of matrix metalloproteinases

Indexed keywords

AZATHIOPRINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN; METHYLPREDNISOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MOTOR NEUROPATHY; NEUROMUSCULAR DISEASE; PATIENT MONITORING; POLYMYOSITIS; PRIORITY JOURNAL; RELAPSE; TISSUE INJURY; TISSUE REPAIR;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOSITIS, INCLUSION BODY; NEUROMUSCULAR DISEASES; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33746788072     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093870     Document Type: Article

References (14)

1. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological action and therapeutic opportunities. J Cell Sci 2002;115:3719-3727.
2. Carmeli E, Moas M, Reznick AZ, Coleman R: Matrix metalloproteinases and skeletal muscle: a brief review. Muscle Nerve 2004;29:191-197.
3. Kugler A: Matrix metalloproteinases and their inhibitors. Anticancer Res 1999;19:1589-1592.
4. Choi YC, Dalakas MC: Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000;54:65-71.
5. Hartung HP, Kieseier BC: The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000;107:140-147.
6. Kieseier BC, Schneider C, Clements JM, Gearing AJ, Gold R, Toyka KV, Hartung HP: Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 2001;124:341-351.
7. Schoser BGH, Blottner D, Stuerenburg HJ: Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol Scand 2002;105:309-313.
8. Demestre M, Wells GM, Miller KM, Smith KJ, Hughes RAC, Gearing AJ, Gregson NA: Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience 2004;124:767-779.
9. Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004;102:177-193.
10. Wiles CM, Brown P, Chapel H, et al: Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosug Psychiatry 2002;72:440-448.
11. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K: Serum gelatinases B, TIMP-1 and TIMP-2 levels in multiple sclerosis. Brain 1999;122:191-197.
12. Mirowska D, Wicha W, Czlonkowski A, Czlonkowska A, Weber F: Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 2004;146:171-175.
13. Sharshar T, Durand MC, Lefaucheur JP, Lofaso F, Raphael JC, Gherardi RK, Creange A: MMP-9 correlates with electrophysiological abnormalities in Guillain-Barré syndrome. Neurology 2002;59:1649-1651.
14. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N: Intravenous γ-globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002;95:2032-2037.